Skip to main content
. Author manuscript; available in PMC: 2013 Apr 25.
Published in final edited form as: Leukemia. 2011 Nov 4;26(5):1116–1119. doi: 10.1038/leu.2011.303

Figure 2. The proteasome-aggresome-phagosome system modulates β-catenin accumulation in MM cells.

Figure 2

(A) β-catenin accumulation in aggresomes after 6 hours of 5nM bortezomib treatment in MM1S cells (top, white arrows). Increased β-catenin in MM xenograft mice treated with bortezomib at 0.5mg/kg twice weekly i.p. for 3 weeks (bottom). (B) IB (top) and IP (bottom) of β-catenin following 2nM bortezomib treatment of MM1S. (C) β-catenin in INA-6 cells grown in vitro and in vivo, respectively. Note distinct perinuclear β-catenin localization (arrows and inset). (D) Enhanced LC3 activation and decreased phospho-β-catenin levels in rapamycin-treated MM1S cells. (E) IFC and SEM analysis demonstrating rapamycin treatment (50nM for 48 hours) of MM1S and OPM1 cells enhanced phagosome formation (white arrows and yellow arrowheads). Inserts: autophagasomes.

HHS Vulnerability Disclosure